AbbVie and Ichnos Glenmark Innovation (IGI) have entered into a significant exclusive global licensing agreement for ISB 2001, a groundbreaking first-in-class CD38xBCMAxCD3 trispecific antibody. This innovative therapeutic was developed using IGI's proprietary BEAT® protein platform, which is designed to create highly effective multispecific antibodies. The agreement grants AbbVie comprehensive rights to develop, manufacture, and commercialize ISB 2001 across key markets including North America, Europe, Japan, and Greater China, with applications planned for both oncology and autoimmune diseases.

ISB 2001 is currently in Phase 1 clinical trials for patients with relapsed/refractory multiple myeloma (R/R MM). Initial data, recently presented at the 2025 ASCO Annual Meeting, has been highly encouraging. The trials showed a remarkable 79% overall response rate (ORR) and a 30% complete/stringent complete response (CR/sCR) rate at active doses in a heavily pretreated patient population, all while maintaining a favorable safety profile. These promising results led to the U.S. Food & Drug Administration granting ISB 2001 Orphan Drug Designation in July 2023 and Fast Track Designation in May 2025, highlighting its potential to address a significant unmet medical need.

Financially, the agreement is substantial. IGI will receive an upfront payment of $700 million and stands to gain up to an additional $1.225 billion in development, regulatory, and commercial milestone payments. Furthermore, IGI will receive tiered, double-digit royalties on net sales. This partnership reflects AbbVie's unwavering commitment to advancing novel therapies for multiple myeloma and IGI's dedication to leveraging its BEAT® platform to deliver meaningful treatments for hard-to-treat cancers. The collaboration aims to accelerate ISB 2001's path to market and, ultimately, to the patients who urgently need new treatment options.